$1.1m in OPAL-Tokenised Product Sales in First 7 Weeks
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The company highlights a rapid acceleration in sales and network growth, demonstrating strong consumer demand for premium Australian brands in the China market. Non-Executive Chairman Dr. Anthony Noble emphasized the significance of these results as validation of the OPAL-Tokenised sales ecosystem.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Xenitra
- XEN Appointed as Exclusive Biomiq Skincare China Distributor
- Product sales of $500k in first month of OPAL token launch
- $1.25m Raised to Support Next Phase of Growth
- OPAL token launch of EZZ products sells $100k in first week
- Q3 Sales rise by over 305% to $8.3m
Later from Xenitra
- $12M offtake agreement with leading OTC-pharmaceutical
- $5m Offtake Agreement Expands OTC-Medicine Business
- Xenitra Raises $1.5m to Accelerate High-Margin Sales Growth
- Appendix 4E and Annual Report
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Xenitra into a list and get an email when it puts out news.
Follow Xenitra